Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now central to the management of type 2 diabetes and obesity, but their benefits often come with gastrointestinal (GI) effects that can impact quality of life and adherence. Alongside recognised changes in gastric emptying and appetite, emerging data suggest that GLP-1 medication and gut health are connected through bidirectional interactions with the gut microbiome1,2,3.
This article reviews common GI side effects, the evolving evidence on GLP-1 and the gut microbiome, and nutritional and probiotic strategies that may help support patients during treatment.
GLP-1 RAs, including liraglutide, semaglutide, dulaglutide, exenatide and newer multi-agonists such as tirzepatide, mimic endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and promote satiety4,5. Large outcome trials in type 2 diabetes have shown improvements in HbA1c, weight and cardiovascular endpoints, leading to broader use in people with obesity, with and without diabetes4,6,7.
However, this same mechanism of action underpins many of the GI symptoms reported in practice. By slowing gastric and small-bowel transit and acting on central emetic pathways, GLP-1 RAs commonly cause bloating, nausea, vomiting and altered bowel habits, particularly during dose escalation8,9.
Understanding these effects and how to manage them is important for optimising long-term adherence to this medication.
Across randomised controlled trials and real-world data, GI adverse events are the most frequent side effects of GLP-1 RAs. A recent meta-analysis of 48 randomised controlled trials in more than 27,000 adults found that nausea, diarrhoea, vomiting and constipation occurred in approximately 12–25% of treated patients, with nausea being the most common10. Head-to-head trials such as SUSTAIN-7, comparing semaglutide with dulaglutide, report similar patterns: semaglutide produced greater weight loss but with GI disorders reported in around 43–44% of participants, compared with 33–48% with dulaglutide. GI symptoms were the leading cause of treatment discontinuation in both groups4.
GLP-1 bloating and nausea are usually most prominent during dose escalation. This may be due to multiple factors:
Semaglutide studies in adults with obesity or type 2 diabetes show reduced energy intake and appetite, with evidence of delayed gastric emptying in some settings11,12. Symptoms often improve over time, but persistent vomiting, severe abdominal pain or inability to maintain hydration should prompt reassessment.
Other pharmacovigilance and cohort studies have added signals for less common but clinically important events, including gallbladder disease, pancreatitis, ileus and possible gastroparesis13,14. While absolute risk remains low, these findings reinforce the need to distinguish expected GLP-1-related nausea from red-flag symptoms such as persistent severe abdominal pain, recurrent vomiting, jaundice or features of bowel obstruction. For most patients, GI symptoms peak during dose escalation and can be mitigated with slower titration, dietary adaptation and supportive measures.
Interest in GLP-1 and gut microbiome interactions is growing, but human evidence remains early. In adults with type 2 diabetes or obesity, liraglutide and dulaglutide have been associated with increases in Akkermansia, Bacteroides and short-chain-fatty-acid-producing taxa such as Faecalibacterium, alongside reductions in potentially pro-inflammatory microbes15,16.
Early human studies in type 2 diabetes also report significant changes in microbial composition and enrichment of potentially beneficial taxa after 12 weeks of semaglutide, but effects on overall diversity have been small or inconsistent and are difficult to disentangle from concurrent calorie restriction and weight loss17,18.
Changes in microbial composition under GLP-1 therapy often parallel improvements in metabolic and inflammatory markers. Akkermansia and short-chain-fatty-acid-producing genera are associated with better gut barrier integrity, lower endotoxaemia and improved insulin sensitivity2. At the same time, weight loss and reduced intake of ultra-processed, high-fat foods may decrease exposure to pro-inflammatory dietary mediators such as lipopolysaccharides, potentially dampening systemic and skin-relevant inflammation19.
There is also evidence that microbial metabolites, including short-chain fatty acids and secondary bile acids, can stimulate endogenous GLP-1 release, suggesting bidirectional crosstalk between GLP-1 signalling and the microbiota20. Clinically, however, routine microbiome testing or microbiome-targeted adjuncts to GLP-1 therapy are not yet recommended. Current data are exploratory and do not support specific microbiome-optimising regimens.
Nutrition support for those on GLP-1 RAs should begin before or at initiation of treatment. Loss of appetite and early satiety can lead to reduced overall energy intake and, in some patients, inadequate protein and micronutrient consumption.
Many adults on GLP-1 therapy may benefit from a moderate-to-high protein intake, for example around 1.2–2.0 g/kg/day, distributed across meals and emphasising lean meats, fish, eggs, dairy, soy and pulses21.
Fibre is important for gut health on GLP-1 RAs because bacterial fermentation of dietary fibre produces short-chain fatty acids such as acetate, propionate and butyrate, which support barrier integrity, modulate inflammation and can stimulate endogenous GLP-1 secretion22,23. Although there is currently a lack of human clinical trials evaluating fibre for GLP-1 RA side effects, maintaining or modestly increasing fibre intake is generally recommended to help counter constipation24,25. However, large, sudden increases may worsen bloating or fullness when gastric emptying is already slowed.
Other behavioural changes can help patients manage GLP-1 bloating and nausea. Practical recommendations include26:
The best foods while taking GLP-1 medication are typically nutrient-dense, lower-fat and lower-grease options that are easier to tolerate in smaller portions. Large, fatty, spicy or alcohol-containing meals can aggravate nausea, reflux and delayed gastric emptying.
Although there are currently no clinical trials specifically evaluating probiotics with GLP-1 medications, broader GI literature suggests a potential role for gut health support during GLP-1 therapy, particularly for symptoms such as bloating, gas, constipation, diarrhoea and abdominal discomfort.
A double-blind trial of Lactobacillus acidophilus NCFM plus Bifidobacterium lactis Bi-07 improved bloating in patients with functional bowel disorders27. Bacillus coagulans MTCC 5856 improved gas and bloating symptoms in adults in another randomised placebo-controlled study28. In functional constipation, probiotic-containing products have improved bowel frequency, stool consistency or constipation symptoms in several adult trials, although effects vary by formulation and population29,30. In diarrhoea-predominant IBS, Lactiplantibacillus plantarum APsulloc 331261 reduced abdominal pain, bloating, incomplete evacuation and diarrhoea frequency versus placebo31.
Probiotics are not a single intervention, and the same effects cannot be assumed across species, strains or doses. Probiotics should be selected according to the target symptom, evidence, immune status and patient preference.
Most GLP-1 gastrointestinal symptoms are mild to moderate and can often be managed by slower titration, dose reduction, temporary interruption or switching therapy. However, persistent vomiting, dehydration, suspected pancreatitis or gallbladder disease warrant review and investigation. Alarm symptoms such as dysphagia, gastrointestinal bleeding or unexplained weight loss should follow standard urgent referral pathways9,32,33.
GLP-1 medication and gut health are best managed proactively rather than reactively. For many patients, nausea, bloating, constipation or diarrhoea are most noticeable during dose escalation and often reflect the expected effects of GLP-1 therapy on gastric emptying, appetite and gut motility.
Microbiome evidence is still emerging in humans, but it points to an important opportunity: supporting the gut environment during treatment may help patients feel more comfortable and maintain better nutritional habits.
In practice, the foundations remain simple: protect protein intake, increase fibre gradually, maintain hydration, use smaller meals and identify foods or habits that worsen symptoms.
Probiotics may be a useful addition for selected patients, particularly where bloating, constipation or diarrhoea affect adherence or quality of life. The key is to choose clinically studied strains and set realistic expectations, as benefits are likely to be symptom-specific rather than universal.
The Biomel Professional Page is a dedicated resource created by our nutrition team to provide healthcare
professionals with reliable, up-to-date information in the gut health space. The content is research-backed,
educational, and strictly non-commercial, focusing on scientific insights beyond our product range.
For customer-friendly resources, the Biomel
Gut Health Articles offers accessible information designed
to support individuals in making informed decisions about their digestive wellness.
